Clinical trial · Observational
The Aim is to Identify Recurrent Genomic Mutations and/or Predisposing Polymorphisms in Patients With Sporadic Cases of Multiple Myeloma
Analysis of Genomic Alterations in Sporadic Cases of Multiple Myeloma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
There is a growing body of data suggesting that the the risk of developing multiple myeloma, or myelomagenesis, is associated with genetic alterations occurring in the tumor cells. A limited number of candidate genes and polymorphisms have been reported in patients with this disease. In this study the investigators will compare the genetic information obtained on purified abnormal plasmocytes obtained from patients with multiple myeloma with available public databases in an effort to identify and if possible validate the role of certain mutations and/or polymorphisms in myelomagenesis. Plasmocytes will be obtained by immunomagnetic enrichment using CD138+ beads.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| DNA sequencing | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- patients with a diagnosis of multiple myeloma
- description
- This study will involve a single patient group, namely patients with a diagnosis of multiple myeloma diagnosed by a bone marrow aspirate with cytological analysis of the bone marrow smear.Bone marrow samples obtained during the routine follow-up will undergo plasmocyte enrichment using immunopurification using CD138+ beads and nucleic acids will be extracted for sequencing.
- interventionNames
- Genetic: DNA sequencing
Primary outcomes (6)
- measure
- DNA mutations associated with the existence of multiple myeloma
- timeFrame
- baseline, pre-intervention/procedure/surgery
- description
- DNA data acquired in myeloma patient samples will be compared to those of healthy subjects using publically available databases.
- measure
- DNA mutations associated with the existence of multiple myeloma
- timeFrame
- during the intervention/procedure/surgery
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * diagnosis of multiple myeloma * availability of abnormal plasmocytes Exclusion Criteria: \- none
References
Publications (0)
Data not yet available